| Emtricitabine and Tenofovir Disoproxil Fumarate | Gilead | ||
| 200MG; 300MG TABLET;ORAL |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
More Than 5
|
None | ||
|
More Than 5
|
More Than 5
|
||
| Indications for TRUVADA: HIV-1 infection, in combination with other antiretroviral agents. Pre-exposure prophylaxis (PrEP) to reduce risk of sexually acquired HIV-1 in high-risk uninfected adults and adolescents in combination with safer sex practices. | |||
|
Yes
| |||
| Truvada | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 |
|---|---|---|---|---|---|---|
| **** | ******* | ******* | ******* | ******* | ******* | ******* |
| ***** | ******* | ******* | ******* | ******* | ******* | ******* |
| ***** | ******* | ******* | ******* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| **** | *** \ *** | **** *, **** | ******* | ******** | ******** ** *** *, **** |
| ***** | ** \ ** | *** **, **** | ******* | ******** | ******** ** *** **, **** |
| ***** | ** \ ** | *** *, **** | ******* | ******** | ******** ** *** **, **** |
| Emtricitabine and Tenofovir Disoproxil Fumarate | Gilead | ||
| 100;150mg, 133;200mg, 167;250mg, Tablet, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
|
Less Than 5
|
Less Than 5
|
||
| None | |||
|
No
| |||
| Truvada | Patent 1 | Patent 2 |
|---|---|---|
| ****** | ******* | ******* |
| ********* | ******* | ******* |
| ***** ****** | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ****** | *** \ *** | *** **, **** | ******* | ******** | ******** ** *** **** |
| ********* | ** \ ** | *** **, **** | ******* | ******** | ******** ** *** **, **** |
| ***** ****** | ** \ ** | **** **, **** | ******* | ******** | ******** ** *** **** |
Download ParaIV Report